Saturday 17 October 2026
Export CLSDQ’s income statement to Excel — free account
Clearside Biomedical, Inc.
CLSDQ Healthcare Biotechnology
Clearside Biomedical, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.7 million, down 79.8% from fiscal 2023. In the quarter to September 2025, revenue fell 80.6%, EPS grew 24.0% and free cash flow grew 8.15%, each against the same quarter a year earlier.
0.25
0.00
0.00%
Follow CLSDQ
| Sep '25 | Jun '25 | Mar '25 | Dec '24 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
6.24 | 14.96 | 18.77 | 42.16 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(3.79) | (13.18) | (12.12) | (13.35) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
4.61 | 13.04 | 15.51 | 30.95 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.72) | (2.50) | (2.58) | (2.09) | |
EV/FCF |
(0.71) | (2.44) | (2.47) | (2.01) | |
Quick Ratio |
2.55 | 3.34 | 3.03 | 4.28 | |
Current Ratio |
2.98 | 3.87 | 3.19 | 4.44 | |
Net Debt/EBITDA |
0.98 | 2.69 | 2.66 | 2.81 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.16 | 0.17 | 0.13 | 0.06 | |
Operating CF/Net income |
0.92 | 1.05 | 0.71 | 0.72 | |
Capex/Depreciation |
0.00 | 0.00 | (0.11) | (17.08) | |
Research and Development Expense of Revenue |
1,459.20% | 321.95% | 191.55% | 1,386.93% | |
Selling, General and Administrative Expense of Revenue |
2,143.28% | 503.25% | 121.20% | 1,000.65% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
371.14% | 141.06% | 30.94% | 381.05% | |
Graham Net Nets |
(2.76) | (0.84) | (0.70) | (0.61) | |
Graham Number |
34.69 | 34.23 | 35.18 | 35.38 | |
Earnings Yield |
(130.68%) | (46.23%) | (44.64%) | (49.45%) | |
Free Cash Flow Yield |
(104.65%) | (35.68%) | (33.41%) | (36.60%) | |
Revenue per Share |
0.04 | 0.09 | 0.45 | 0.06 | |
Operating CF per Share |
(1.05) | (0.91) | (1.14) | (1.07) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.09) | |
Free Cash Flow per Share |
(1.05) | (0.91) | (1.14) | (1.16) | |
Cash per Share |
1.30 | 1.81 | 2.66 | 4.07 | |
Shareholders Equity per Share |
(10.31) | (9.39) | (8.95) | (7.89) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(10.31) | (9.39) | (8.95) | (7.89) | |
Free Cash Flow |
(5.48) | (4.73) | (5.84) | (5.70) | |
Working Capital |
5.48 | 8.74 | 10.95 | 16.48 | |
Capital Expenditures |
0.00 | 0.00 | (0.01) | (0.44) | |
Net Current Asset Value |
(57.34) | (52.28) | (49.61) | (42.71) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 1.45 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.53 | 0.64 | 1.21 | 0.38 | |
Average Payables |
1.58 | 1.35 | 1.64 | 1.83 | |
Average Assets |
20.40 | 24.63 | 29.91 | 29.57 | |
Average Common Equity |
(44.37) | (38.51) | (33.86) | (27.38) |
Columns are period end dates